联合开发心脏药物III期试验未达主要终点阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌

智通财经07-09

【联合开发心脏药物III期试验未达主要终点阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌】智通财经APP获悉，阿斯利康(AZN.US)与Ionis(IONS.US)联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，该股伦敦挂牌股价周三暴跌近10%，截至发稿，周三美股盘前跌8.67%，Ionis股价盘前亦下跌逾8%。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2650929827?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-07-09 19:29","share_image_url":"https://static.laohu8.com/6ca2dcdccfa2217fb20a0351f4efe814","id":"2650929827","market":"us","top_or_hot":-1,"title":"联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌","media":"智通财经","content":"<html><body><div>\n<div>\n<b>【联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌】</b>智通财经APP获悉，阿斯利康(AZN.US)与Ionis(IONS.US)联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，该股伦敦挂牌股价周三暴跌近10%，截至发稿，周三美股盘前跌8.67%，Ionis股价盘前亦下跌逾8%。                </div>\n</div></body></html>","source":"live_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌\n</h2>\n\n<h4 class=\"meta\">\n\n</h4>\n\n</header>\n<article>\n<html><body><div>\n<div>\n<b>【联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌】</b>智通财经APP获悉，阿斯利康(AZN.US)与Ionis(IONS.US)联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，该股伦敦挂牌股价周三暴跌近10%，截至发稿，周三美股盘前跌8.67%，Ionis股价盘前亦下跌逾8%。                </div>\n</div></body></html>\n\n<div class=\"bt-text\">\n\n\n<p> 来源：<a href=\"https://www.zhitongcaijing.com/immediately.html?type=usstock\">智通财经</a> </p>\n\n<p>为提升您的阅读体验，我们对本页面进行了排版优化</p>\n\n</div>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2237443978.SGD","symbol_name":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","start_time":0,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","article_id":"2650929827","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2650929827","pubTimestamp":1783596558,"columns":[],"sourceInfo":{"source_id":"live_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"【联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌】智通财经APP获悉，阿斯利康(AZN.US)与Ionis(IONS.US)联合开发的一款实验","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"LU2237443978.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc SGD-H","BK4568":"美国抗疫概念","BK4588":"碎股","LU2089984988.USD":"MANULIFE GF HEALTHCARE \"AA\" (USD) ACC","AZNH":"ASTRAZENECA PLC ADRhedged","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","III":"信息服务","BK4134":"信息科技咨询与其它服务","LU2456880835.USD":"ALLIANZ GLOBAL INCOME \"AT\" (USD) ACC","AZN":"阿斯利康","BK4007":"制药","LU0708994859.HKD":"TEMPLETON GLOBAL \"A\" (HKD) ACC","LU1829250122.USD":"高盛欧洲核心股票组合Acc","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU2462157665.USD":"ALLIANZ GLOBAL INCOME \"A\" (USD) INC","LU2237443622.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A Acc USD","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0029864427.USD":"TEMPLETON GLOBAL \"A\" (USD) INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","LU2417539215.USD":"ALLIANZ GLOBAL INCOME \"AMF\" (USD) INC","LU2236285917.USD":"ALLIANZ GLOBAL INCOME \"AMG\" (USD) INC","BK4585":"ETF&股票定投概念","LU0128525929.USD":"TEMPLETON GLOBAL \"A\" (USD) ACC","BK4139":"生物科技","IONS":"Ionis Pharmaceuticals, Inc","IE00B3T34201.USD":"BNY MELLON GLOBAL EQUITY INCOME \"B\" (USD) INC","LU0058720904.USD":"联博国际健康护理基金A","LU2237443382.USD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA USD","LU0310800379.SGD":"FTIF - Templeton Global A Acc SGD","LU2468319806.SGD":"MANULIFE GF HEALTHCARE \"AA\" (SGDHDG) ACC","LU2237443549.SGD":"Aberdeen Standard SICAV I - Global Dynamic Dividend A MIncA SGD-H","LU0289739699.SGD":"AB INTERNATIONAL HEALTH CARE PORTFOLIO \"A\" (SGD) ACC","LU2237443895.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) ACC","LU2237443465.HKD":"abrdn SICAV I -  GLOBAL DYNAMIC DIVIDEND \"A\" (HKD) INC","LU1267930573.SGD":"TEMPLETON GLOBAL \"AA\" (SGD) ACC A"},"translate_title":"Jointly Developed Heart Drug Phase III Trial Misses Primary Endpoint AstraZeneca (AZN.US) and Ionis (IONS.US) Shares Plunge","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AZN":1.5,"III":1.5,"IONS":1.5,"AZNH":0.6},"content_text":"【联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌】智通财经APP获悉，阿斯利康(AZN.US)与Ionis(IONS.US)联合开发的一款实验性心脏病药物在后期临床试验中未能达到主要疗效终点，该股伦敦挂牌股价周三暴跌近10%，截至发稿，周三美股盘前跌8.67%，Ionis股价盘前亦下跌逾8%。","kind":"live","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2650929827","isCrawlerRequest":true}

联合开发心脏药物III期试验未达主要终点 阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌

精彩评论

联合开发心脏药物III期试验未达主要终点阿斯利康(AZN.US)与Ionis(IONS.US)股价暴跌